A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7.28055103
   PubMed Web of Science ®Google Scholar
• Oronsky B, Ray CM, Spira AI, et al. A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. Med Oncol. 2017;34(6):103. doi:10.1007/s12032-017-0960-z28444622
   PubMed Web of Science ®Google Scholar
• Ferrero A, Ditto A, Giorda G, et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. Eur J Surg Oncol. 2014;40(7):891–898. doi:10.1016/j.ejso.2013.11.02624378007
   PubMed Web of Science ®Google Scholar
• Colombo N. 327 Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2). Eur J Cancer. 2003;1(5):S101–S101.
   Google Scholar
• Naumann DRW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397–1412. doi:10.2165/11591720-000000000-0000021812505
   PubMed Web of Science ®Google Scholar
• Heintz A, Odicino F, Maisonneuve P, et al. Carcinoma of the Ovary. Int J Gynecol Obstet. 2006;83(3):p. 135–166. doi:10.1016/S0020-7292(03)90118-4
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer[EB/OL]; 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 319, 2021.
   Google Scholar
• Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8. doi:10.1016/j.ygyno.2004.07.01115385103
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890–896. doi:10.1200/JCO.2007.13.660618281662
   PubMed Web of Science ®Google Scholar
• Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res. 2011;3:219–225. doi:10.2147/CMAR.S1555821792330
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405–410. doi:10.1200/JCO.1998.16.2.4059469322
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Ball HG, et al. A Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130–135. doi:10.1016/S0090-8258(02)00091-412586591
   PubMed Web of Science ®Google Scholar
• Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–2612. doi:10.1093/annonc/mds20322910840
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus H, New A. Initiative on precision medicine. New Engl J Med. 2015;372(9):793–795. doi:10.1056/NEJMp150052325635347
   PubMed Web of Science ®Google Scholar
• Birgitta S, Gerhards R, Strumberg D, et al. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010;136(9):1389–1400. doi:10.1007/s00432-010-0790-220217132
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Matsuzaki I, Nishino M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. J Clin Pathol. 2018;jclinpath-2017-204928.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status. J Clin Oncol. 2005;2(1):35–37.
   Google Scholar
• Weroha SJ, Oberg AL, Ziegler KLA, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2011;122(1):116–120. doi:10.1016/j.ygyno.2011.03.03021514634
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double- blind, placebo controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045. doi:10.1200/JCO.2012.42.050522529265
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012;30(15_suppl):LBA5002–LBA5002. doi:10.1200/jco.2012.30.15_suppl.lba5002
   Google Scholar
• Ray-Coquard IL, Pautier P, et al. Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. presented at ESMO Annual Conference 2019, 27 September - 1 October. Barcelona, Spain.
   Google Scholar
• Scott CL, Becker MA, Haluska P, et al. Patient -derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013;3:295. doi:10.3389/fonc.2013.0029524363999
   PubMedGoogle Scholar
• Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol. 2014;8(3):656–668. doi:10.1016/j.molonc.2014.01.00824560445
   PubMed Web of Science ®Google Scholar
• Letai A. Functional precision cancer medicine—moving beyond pure genomics. Nat Med. 2017;23(9):1028–1035. doi:10.1038/nm.438928886003
   PubMed Web of Science ®Google Scholar
• Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7(5):462. doi:10.1158/2159-8290.CD-16-115428331002
   PubMed Web of Science ®Google Scholar
• Friedman AA, Letai A, Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15(12):747–756. doi:10.1038/nrc401526536825
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013. doi:10.1158/2159-8290.CD-14-000125185190
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang W, Long Y, et al. The establishment of mini-PDX models for predicting the clinical treatment plan. Chin J Cancer. 2019;4.
   Google Scholar
• Ming Z, Rui-Meng Y, Hui W, et al. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun. 2018;38(1):48. doi:10.1186/s40880-018-0318-8
   Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165.18024863
   PubMed Web of Science ®Google Scholar
• Chun-Yan L, Yin W, Ying X, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a Phase 2, single-arm, prospective study. Lancet Oncol. 2018;S147020451830349–8.
   Web of Science ®Google Scholar
• Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2015;S0090825815302237.
   Web of Science ®Google Scholar
• Dal MGZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol. 2018;fon-2018-0215.
   Web of Science ®Google Scholar
• Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636–648. doi:10.1016/S1470-2045(19)30029-430948273
   PubMed Web of Science ®Google Scholar
• Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744–750. doi:10.1038/s41591-019-0407-531011206
   PubMed Web of Science ®Google Scholar
• Heo EJ, Cho YJ, Cho WC, et al. Patient-derived xenograft models of epithelial ovarian cancer for preclinical studies. Technol Cancer Res T. 2017;49(4):915–926. doi:10.4143/crt.2016.322
   PubMed Web of Science ®Google Scholar
• Ricci F, Guffanti F, Damia G, et al. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. Mol Cancer. 2017;16(1):97. doi:10.1186/s12943-017-0662-328558767
   PubMed Web of Science ®Google Scholar